Announcements
Reviews in Cardiovascular Medicine (RCM) is published by IMR Press from Volume 19 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with MedReviews, LLC.
Volume 2 Issue S1 2001
Order by
NULL
- Open Access ReviewRadiocontrast-Induced Acute Renal Failure: Allocations and OutcomesRoxana Mehran, Dale T. AshbyRev. Cardiovasc. Med. 2001, 2(S1), 9–13;213Downloads73Views
- Open Access IntroductionRadiocontrast Nephropathy: Managing the High-Risk PatientNorman E. LeporRev. Cardiovasc. Med. 2001, 2(S1), 1–3;102Downloads43Views
- Open Access ReviewManaging the High-Risk Patient: Experience with Fenoldopam, a Selective Dopamine Receptor Agonist, in Prevention of Radiocontrast Nephropathy During Percutaneous Coronary InterventionAnnapoorna Kini, Samin K. SharmaRev. Cardiovasc. Med. 2001, 2(S1), 19–25;99Downloads87Views
- Open Access ReviewPathophysiology of Radiocontrast Nephropathy and Use of Fenoldopam for Its PreventionVandana S. MathurRev. Cardiovasc. Med. 2001, 2(S1), 4–8;127Downloads59Views
- Open Access ReviewPast and Present Attempts to Prevent Radiocontrast NephropathySteven R. BaileyRev. Cardiovasc. Med. 2001, 2(S1), 14–18;56Downloads83Views
- Open Access ReviewClinical Experience with the Use of Fenoldopam for Prevention of Radiocontrast Nephropathy in High-Risk PatientsHooman MadyoonRev. Cardiovasc. Med. 2001, 2(S1), 26–30;76Downloads66Views
- Open Access ReviewDesign and Rationale of CONTRAST--A Prospective, Randomized, Placebo-Controlled Trial of Fenoldopam Mesylate for the Prevention of Radiocontrast NephropathyGrgg W. Ston e, James A.Tu mlin, Hooman Madyoon, NormanE. Lepor, ... William W.O'NeilRev. Cardiovasc. Med. 2001, 2(S1), 31–36;80Downloads55Views